Herceptin: mechanisms of action and resistance
Top Cited Papers
- 28 March 2005
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 232 (2), 123-138
- https://doi.org/10.1016/j.canlet.2005.01.041
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast CancerClinical Cancer Research, 2004
- Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment aloneCancer, 2003
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancerBritish Journal of Surgery, 2002
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Activated neu Induces Rapid Tumor ProgressionJournal of Biological Chemistry, 1996
- Bispecific HER2 × CD3 Antibodies Enhance T-Cell Cytotoxicity in Vitro and Localize to HER2-Overexpressing Xenografts in Nude MiceClinical Immunology and Immunopathology, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987